Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Gill

Showing results (121-130 of 143) with videos related to

Pageof 15
Sort By:
Leukemia & Lymphoma|February 21, 2022
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamideCraig W Freyer, Alison Carulli, Shannon Gier, et al.
Transplantation and Cellular Therapy|November 6, 2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid MalignanciesMatthew P Connor, Alison W Loren, Elizabeth O Hexner, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]P Bigot, J Bernhard, G Verhoest, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]P Bigot, J Bernhard, I Gill, et al.
Blood Advances|May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
American Journal of Hematology|June 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Food & Function|April 23, 2025
Extended recommendations on the nomenclature for microbial catabolites of dietary (poly)phenols, with a focus on isomersClaudio Curti, Michael N Clifford, Colin D Kay, et al.
Nature Medicine|October 3, 2018
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cellMarco Ruella, Jun Xu, David M Barrett, et al.
Transplantation and Cellular Therapy|January 19, 2024
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation RecipientsAnthony D Sung, Thuy Koll, Shannon H Gier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|January 15, 2018
Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCRB Reix, J-C Bernhard, J-J Patard, et al.
Pageof 15

Showing results (121-130 of 143) with videos related to

Sort By:
Pageof 15
Leukemia & Lymphoma|February 21, 2022
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamideCraig W Freyer, Alison Carulli, Shannon Gier, et al.
Transplantation and Cellular Therapy|November 6, 2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid MalignanciesMatthew P Connor, Alison W Loren, Elizabeth O Hexner, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]P Bigot, J Bernhard, G Verhoest, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]P Bigot, J Bernhard, I Gill, et al.
Blood Advances|May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
American Journal of Hematology|June 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Food & Function|April 23, 2025
Extended recommendations on the nomenclature for microbial catabolites of dietary (poly)phenols, with a focus on isomersClaudio Curti, Michael N Clifford, Colin D Kay, et al.
Nature Medicine|October 3, 2018
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cellMarco Ruella, Jun Xu, David M Barrett, et al.
Transplantation and Cellular Therapy|January 19, 2024
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation RecipientsAnthony D Sung, Thuy Koll, Shannon H Gier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|January 15, 2018
Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCRB Reix, J-C Bernhard, J-J Patard, et al.
Pageof 15